Immunicum AB: Immunicums the CEO presents the company at the conferences in June

Press release

30 May 2017

Immunicums the CEO presents the company at the conferences in June

Immunicum AB

(publ; First North Premier: IMMU.ST), a biotechnology company that develops new immunaktiverande cancer treatments for a number of solid tumors, announced today that Carlos de Sousa, CEO of Immunicum, has been invited to present the company at a number of conferences in June and has also been asked to participate in a panel entitled “New Frontiers in Oncology.” In addition, the company will participate in the 2017 BIO International Convention.

Sachs Associates 3rd Annual Immuno-Oncology BD&L and Investment Forum

Date: June 2, 2017

Time for Immunicums presentation: 11:10 CST

Location: Hyatt Centric Chicago Magnificent Mile Hotel, Chicago, Illinois

Labiotech Refresh

Date: June 8, 2017

Panel discussion: “New Frontiers in Oncology” 10:30 CET

Location: Spreewerkstätten, Berlin, Germany


Date: June 12, 2017

Time for Immunicums presentation: 9:20 – 9:50 CET

Location: Sheraton Hotel Stockholm, Stockholm, Sweden

For those who can not attend so the presentation will from Småbolagsdagen be available afterwards on the Immunicums website and can also be followed live on the

2017 BIO International Convention

(only participants)

Dates: 19-22 June, 2017

Location: San Diego Convention Center, San Diego, California

For further information, please contact:

Carlos de Sousa, CEO, Immunicum

Telephone: +46 (0) 31 41 50 52


Investor Relations, Sweden

Helena Stångberg

Hallvarsson & Halvarsson

Telephone: + 46 709 71 12 53


Investor relations and media contact, EUROPE/USA

MacDougall Biomedical Communications

Gretchen Schweitzer or Stephanie May

Telephone: +49 89 2424 3494 or + 49 175 571 1562

E-mail: or


The company’s Certified Adviser is Redeye AB

Telephone: +46 (0) 8 545 013 31




Like this post? Please share to your friends:
Leave a Reply